SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D
http://www.w3.org/2000/01/rdf-schema#comment
"Our results suggest for the first time that REV1 and REV3L SNPs might serve as potential predictive markers of outcome of cisplatin-based chemotherapy"
xsd:string
http://purl.uniprot.org/uniprot/#_4F81C270CE1F906F960EDBA3509EFFF5D8236790F1B268C1AFD16CEB1914FD5B3F57F669C73269235EB184FE7C9C1143
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D
http://purl.uniprot.org/uniprot/Q9UID5
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D
http://purl.uniprot.org/uniprot/#_Q9UID5-mappedCitation-24956248
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D88A1994F945B5FA58B8F2222E89695169BB9547BB5B9FAF2DAD608DC424E37AFF4E79148F9E5B383E3323043D22011D